Our Mission

Strengthened by more than 30 years of experience, Precision Lens partners with eye care providers and empowers them with cutting edge technology, exceptional service, and integrity.

ZEISS is one of the world’s leading innovators in the design and development of medical devices. We create and supply cutting-edge technologies and application-oriented solutions for ophthalmology and microsurgery.he world’s leading innovators in the design and development of medical devices. We create and supply cutting-edge technologies and application-oriented solutions for ophthalmology and microsurgery.

Optos, invented ultra-widefield optomap retinal imaging – the ONLY true UWF imaging technology which documents 82% of the retina in a single capture. Over 1,000 peer-reviewed studies confirm that optomap enables doctors to more effectively detect and manage retinal pathology. optomap is revolutionizing eye care and helping doctors save sight and save lives.

Our Mission: To place doctors and patients at the center of care through an intelligent, specialty-specific cloud platform.

Our Vision: A world where the software we build increases medical practice success and improves patient outcomes.

Dompé is an Italian biopharmaceutical company based in Milan with a US subsidiary in the San Francisco Bay Area. It has a 100+ year legacy of medical innovation and is committed to seeking further advances that address unmet medical needs in the areas of ophthalmology and diabetes. This commitment to innovation has resulted in successful development collaborations with over 200 centers of excellence. Dompé’s commitment to ophthalmology includes the first topical biologic FDA-approved for an ophthalmic indication, and continued exploration of potential new indications through ongoing trials.

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Pioneering new treatments for chronic eye diseases: At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

Transforming eye care in Nebraska

The mission of the Stanley M. Truhlsen Eye Institute and the Department of Ophthalmology and Visual Sciences at the University of Nebraska Medical Center is to improve eye care in Nebraska through premier educational programs, innovative research, high quality patient care and outreach to underserved populations.

Our mission is to deliver innovative and clinically superior ophthalmic products that consistently respond to the expectations of our global customers and reward the profound trust placed in us to improve sight and quality of life. Rayner is leading the way in ophthalmic innovation with IOLs and ophthalmic solutions designed to provide surgeons and patients with the best visual outcomes.

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.